Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, Australia, Germany, and the Netherlands.
+ 2 more risks
Adequate balance sheet with limited growth.
Share Price & News
How has Mainstay Medical International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MSTY's share price has been volatile over the past 3 months.
7 Day Return
FR Medical Equipment
1 Year Return
FR Medical Equipment
Return vs Industry: MSTY underperformed the French Medical Equipment industry which returned 63.1% over the past year.
Return vs Market: MSTY underperformed the French Market which returned -8.1% over the past year.
Price Volatility Vs. Market
How volatile is Mainstay Medical International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StThe Mainstay Medical International (EPA:MSTY) Share Price Is Down 86% So Some Shareholders Are Rather Upset
4 weeks ago | Simply Wall StDo Insiders Own Shares In Mainstay Medical International plc (EPA:MSTY)?
1 month ago | Simply Wall StWould Mainstay Medical International (EPA:MSTY) Be Better Off With Less Debt?
Is Mainstay Medical International undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MSTY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MSTY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MSTY is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: MSTY is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MSTY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MSTY is overvalued based on its PB Ratio (977.8x) compared to the FR Medical Equipment industry average (3x).
How is Mainstay Medical International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSTY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MSTY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MSTY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MSTY's revenue (114.1% per year) is forecast to grow faster than the French market (3.9% per year).
High Growth Revenue: MSTY's revenue (114.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MSTY's Return on Equity is forecast to be high in 3 years time
How has Mainstay Medical International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MSTY is currently unprofitable.
Growing Profit Margin: MSTY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MSTY is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare MSTY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSTY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.8%).
Return on Equity
High ROE: MSTY has a negative Return on Equity (-67833.33%), as it is currently unprofitable.
How is Mainstay Medical International's financial position?
Financial Position Analysis
Short Term Liabilities: MSTY's short term assets ($20.2M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: MSTY's short term assets ($20.2M) exceed its long term liabilities ($14.6M).
Debt to Equity History and Analysis
Debt Level: MSTY's debt to equity ratio (52742.4%) is considered high.
Reducing Debt: Insufficient data to determine if MSTY's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MSTY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MSTY has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 17.5% each year.
What is Mainstay Medical International's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MSTY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MSTY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MSTY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MSTY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MSTY's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jason Hannon (47yo)
Mr. Jason Marshall Hannon, Esq. & M.A, is Independent Non-Executive Director at Sequana Medical NV since May 23, 2019. He served as an Independent Non-Executive Director of Kuros Biosciences AG since June ...
CEO Compensation Analysis
Compensation vs Market: Jason's total compensation ($USD823.21K) is above average for companies of similar size in the French market ($USD321.65K).
Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.
|CEO & Director||2.67yrs||US$823.21k||0.22% $64.8k|
|Non-Executive Director||6.17yrs||no data||no data|
|Non-Executive Director||4yrs||no data||0.022% $6.3k|
|Independent Non-Executive Chairman||no data||US$103.91k||no data|
|Independent Non-Executive Director||6.17yrs||US$58.17k||1.59% $459.7k|
|Independent Non-Executive Director||5yrs||US$58.17k||no data|
|Non-Executive Director||6.17yrs||no data||3.84% $1.1m|
Experienced Board: MSTY's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53%.
Mainstay Medical International plc's company bio, employee growth, exchange listings and data sources
- Name: Mainstay Medical International plc
- Ticker: MSTY
- Exchange: ENXTPA
- Founded: 2008
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €28.996m
- Shares outstanding: 13.42m
- Website: https://www.mainstay-medical.com/en
Number of Employees
- Mainstay Medical International plc
- 77 Sir John Rogerson’s Quay
- Block C
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MSTY1||ISE (Irish Stock Exchange)||Yes||New Ordinary Shares||IE||EUR||Apr 2014|
|MSTY||ENXTPA (Euronext Paris)||Yes||New Ordinary Shares||FR||EUR||Apr 2014|
|MSTYP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||New Ordinary Shares||GB||EUR||Apr 2014|
|0QUD||LSE (London Stock Exchange)||Yes||New Ordinary Shares||GB||EUR||Apr 2014|
Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, Australia, Germany, and the Netherlands. It focuses on commercializing ReActiv8, an implantable restorative neurostimulation system to treat people with disabling chronic low back pain. The company was formerly known as Mainstay Medical plc and changed its name to Mainstay Medical International plc in March 2014. Mainstay Medical International plc was founded in 2008 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/02 00:47|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.